HighGravityDataBioMarin Pharmaceutical — Aug 6, 2026 release
Fiscal 2026 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001048477-26-000015
Showing in the filing
VOXZOGO full-year 2026 revenue (CEO quote)
“at least $1 billion”
Period
FY2026
Measure
GAAP-tied
Source
Prose
All guidance in this release · 22
VOXZOGO full-year 2026 revenue (CEO quote) for FY2026
“at least $1 billion”
Peak revenue for GALAFOLD for FY2030
“approximately $1.4 billion”
Peak revenue for POMBILITI + OPFOLDA for FY2030
“approximately $1.2 billion”
Cost reductions from Amicus acquisition (GAA… for FY2028
“approximately $280 million”
Cost reductions on a GAAP basis for FY2028
“approximately $280 million”
Cost reductions from Amicus acquisition (Non… for FY2028
“approximately $220 million”
GALAFOLD and POMBILITI + OPFOLDA, combined, … for FY2030
“over 60%”
Gross leverage target for FY2027
“below 2.5 times”
Interest expense associated with the financing
“approximately $200 million on an annualized basis”
Interest expense related to Amicus financing…
“approximately $200 million”
Total Revenues for FY2026
“$3,875 to $3,925”
Total Revenues Midpoint Growth (Y/Y) for FY2026
“21%”
Metabolic Conditions for FY2026
“$2,725 to $2,775”
Metabolic Conditions Midpoint Growth (Y/Y) for FY2026
“31%”
VOXZOGO Revenue for FY2026
“$1,000 to $1,050”
VOXZOGO Midpoint Growth (Y/Y) for FY2026
“11%”
Other Revenues for FY2026
“$100 to $125”
Metabolic Conditions Revenue for FY2026
“Unchanged”
Non-GAAP Diluted EPS for FY2026
“$4.90 to $5.10”
Non-GAAP Diluted EPS Midpoint Growth (Y/Y) for FY2026
“59%”
Weighted-Average Diluted Shares Outstanding … for FY2026
“approximately 200 million”
Combined company tax rate assumption for Non… for FY2026
“22%”
Exhibit 99.1 · the passage around this item
… earlier in the release
"This quarter, we executed strongly across our portfolio while rapidly integrating Amicus into BioMarin's operations and advancing plans to accelerate growth for GALAFOLD and POMBILITI + OPFOLDA, and extending the benefit of these medicines to more patients worldwide," said Alexander Hardy, President and Chief Executive Officer of BioMarin. “Strong global demand led us to increase full-year VOXZOGO revenue guidance to at least $1 billion in 2026. Adding to this momentum is the opportunity to advance our second potential indication with VOXZOGO, hypochondroplasia, based on recent pivotal data that exceeded our expectations.” Mr. Hardy added, “With our larger, more diversified commercial portfolio of innovative medicines, we are positioned to deliver additional growth and increased profitability. We expect strong execution through the remainder of 2026, bringing together our expanded portfolio, scale and disciplined integration efforts to reach more patients living with serious genetic conditions around the world.” 2026 Business and Pipeline Highlights Innovation • BioMarin recently submitted its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of VOXZOGO for the treatment of hypochondroplasia. If approved, VOXZOGO would be the first targeted therapy for the treatment of hypochondroplasia, with a potential 2027 launch. The company plans to provide an update on the application status as part of its third quarter earnings update. 1 • In May, the company announced that the Phase 3 CANOPY-HCH-3 study of VOXZOGO in children with hypochondroplasia met its primary end
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.